Patient-derived ovarian cancer xenografts re-growing after a cisplatinum treatment are less responsive to a second drug re-challenge: a new experimental setting to study response to therapy

Even if ovarian cancer patients are very responsive to a cisplatinum-based therapy, most will relapse with a resistant disease. New experimental animal models are needed to explore the mechanisms of resistance, to better tailor treatment and improve patient prognosis. To address these aims, seven pa...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncotarget
Asıl Yazarlar: Ricci, Francesca, Fratelli, Maddalena, Guffanti, Federica, Porcu, Luca, Spriano, Filippo, Dell’Anna, Tiziana, Fruscio, Robert, Damia, Giovanna
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Impact Journals LLC 2016
Konular:
Research Paper
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5352333/
https://ncbi.nlm.nih.gov/pubmed/26910918
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.7465
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller